aiqbench analysis
GSK is proactively addressing the dual-use nature of quantum computing by preparing defenses against future decryption risks while simultaneously leveraging the technology for drug discovery. The company recognizes the critical threat of "harvest now, decrypt later" attacks, which could compromise sensitive clinical trial data once Cryptographically Relevant Quantum Computers (CRQC) become viable. This strategic pivot highlights the urgent need for organizations to upgrade cryptographic standards now to protect long-term data integrity against emerging algorithmic vulnerabilities like Shor's and Grover's.
How GSK Prepares for Quantum Threats to Clinical Trial Data
GSK is evaluating how quantum computing impacts cybersecurity, recognizing future systems could compromise data—including sensitive clinical trial.
GlaxoSmithKline is simultaneously exploring the potential of quantum computing to accelerate drug discovery and fortifying its defenses against the cyber security risks the technology introduces. The pharmaceutical company recognizes that the same advances promising to identify novel compounds and optimize clinical trial design also threaten the cryptographic foundations of secure digital communication. At its core, modern cryptography, ensuring confidentiality, integrity, authentication, and non-repudiation, could be challenged by the development of sufficiently powerful quantum computers. GSK states that a proactive approach is essential to protect sensitive research and patient data against future decryption, even from data captured. The established…
Excerpt shown under the publisher's RSS terms · 98 words · full text and figures are on the publisher's site
